Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Squamous Non-small Cell Lung Cancer × 1 year × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 486 Carcinoma, Non-Small-Cell Lung 461 Prostatic Neoplasms 307 Multiple Myeloma 244 Neoplasms 235 Colorectal Neoplasms 223 Leukemia, Myeloid, Acute 200 Lung Neoplasms 195 Squamous Cell Carcinoma of Head and Neck 190 Neoplasm Metastasis 179 Carcinoma, Hepatocellular 173 Pancreatic Neoplasms 164 Melanoma 157 Triple Negative Breast Neoplasms 151 Ovarian Neoplasms 137 Recurrence 136 Glioblastoma 125 Lymphoma 124 Brain Neoplasms 123 Leukemia, Lymphocytic, Chronic, B-Cell 114 Stomach Neoplasms 109 Sarcoma 109 Precursor Cell Lymphoblastic Leukemia-Lymphoma 109 Lymphoma, Large B-Cell, Diffuse 107 Carcinoma, Renal Cell 106 Head and Neck Neoplasms 104 Myelodysplastic Syndromes 96 Uterine Cervical Neoplasms 88 Small Cell Lung Carcinoma 88 Rectal Neoplasms 88

Interventions

pembrolizumab 1 Paclitaxel 1 Carboplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07221474 2026-03-12

INTerpath-13

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡